The DNAJC15 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout population derived from the A2780 human ovarian carcinoma cell line. This product introduces targeted disruption of the DNAJC15 gene, generating a loss-of-function model suitable for investigating mitochondrial function, chemosensitivity, and apoptosis. The polyclonal format provides a heterogeneous pool of edited cells, reflecting a spectrum of genetic modifications, which is ideal for pooled screening or generating mixed populations for functional assays.
A2780 cells are an established epithelial cell line originating from an untreated patient with ovarian endometrioid adenocarcinoma. This widely used model retains key features of ovarian carcinoma and is particularly valuable for studying drug resistance mechanisms. The A2780 background enables researchers to explore how alterations in mitochondrial biology influence tumor cell behavior and therapeutic responses.
DNAJC15 encodes a mitochondrial co-chaperone that interacts with HSPA9 (mortalin) and HSPA1L to modulate the assembly and activity of respiratory chain complex I. As a negative regulator of complex I, DNAJC15 limits electron transport, ATP synthesis, and ROS production. Its expression is regulated by DNA methylation and the transcription factor SP1. Downstream, loss of DNAJC15 enhances mitochondrial complex I activity, altering ATP and ROS levels, and affects the BCL2 family balance, cytochrome c release, and caspase-3 activation, thereby influencing the intrinsic apoptosis pathway and JNK signaling.
In the A2780 ovarian cancer context, DNAJC15 disruption provides a powerful tool to dissect the molecular basis of chemoresistance. Methylation silencing of DNAJC15 has been associated with reduced apoptosis and increased drug resistance, making this knockout model highly relevant for studying how mitochondrial respiratory chain dynamics govern therapy response. The coordinated changes in complex I subunits (such as NDUFA9 and NDUFS3) and apoptotic regulators (including BCL2 and BAX) can be systematically examined to uncover vulnerabilities in chemoresistant ovarian cancer cells.
Researchers can employ these polyclonal knockout cells in a range of functional assays, such as mitochondrial complex I activity measurements, ATP quantification, ROS detection, and apoptosis assays using Western blotting for caspase-3 cleavage and cytochrome c release. Additionally, drug sensitivity profiling and cell viability assays enable direct assessment of therapeutic responses, while immunofluorescence and RT-qPCR facilitate expression analysis. The DNAJC15 Knockout A2780 Polyclonal Cells are an essential resource for unraveling the interplay between mitochondrial co-chaperones, bioenergetics, and apoptosis in ovarian cancer. For additional details, please contact Ascent Research.
